Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M24-600 Upadacitinib in Severe Alopecia Areata (Japan)
jRCT2031250181Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in alopecia areata (4 arms), sponsored by AbbVie Inc. Primary endpoints: SALT response at Week 24 and Adverse events. Started Jun 2025; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2031250181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250181.